NASDAQ · MRUS
Merus N.V.
Healthcare · Biotechnology
$90.00
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 8:44 AM
SID Score
5.5/10
Composite research score
Smart Money
50/100
Neutral
- Market cap
- 7.33B
- P/E ratio
- -20.9
- Dividend yield
- 0.00%
- 52-week range
- $51.78 – $97.14
- Volume
- 2.73M
- Avg. volume
- 2.48M
Price performance
MRUS price history
1M range · 0 trading sessions · Daily adjusted prices
MRUS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest MRUS news
The latest Smart Investors Daily articles mentioning MRUS.
Stock researchCompany · Overview
MRUS research
Overview
Company profile and research snapshot.
Company profile
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $96.22
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2025 | Leerink Partners | Market Perform | — |
| Sep 30, 2025 | Wells Fargo | Equal-Weight | — |
| Sep 30, 2025 | Canaccord Genuity | Hold | — |
| Sep 30, 2025 | Guggenheim | Neutral | — |
| Sep 30, 2025 | LifeSci Capital | Market Perform | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
